NCT03821870View on ClinicalTrials.gov

Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity

CompletedOBSERVATIONAL
Enrollment

12

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

February 22, 2023

Conditions
Metastatic Pancreatic Cancer
Interventions
DIAGNOSTIC_TEST

Inditreat

Tumoroid formation and drug sensitivity analysis

DRUG

Experimental drug

Second line treatment based on drug sensitivity analysis

Trial Locations (1)

Unknown

Departmen of Oncology, Vejle Hospital, Vejle

All Listed Sponsors
lead

Vejle Hospital

OTHER

NCT03821870 - Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity | Biotech Hunter | Biotech Hunter